11 patents
Utility
Substituted Pyridines for the Treatment of Inflammatory Diseases
21 Sep 23
Compounds having the structure of Formula (I) or pharmaceutically acceptable isomers, racemates, hydrates, solvates or salts thereof, where A, R1, R2a, R2b, R2c and R3 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on TYK2 to cause signal transduction inhibition, as well as to pharmaceutical compositions containing the same and to methods of their use and preparation.
Craig Alan Coburn, Chad Alan Van Huis, Thomas Daniel Aicher
Filed: 14 Apr 21
Utility
Compounds Useful As T Cell Activators
31 Aug 23
Anthony Casarez, Terry Kellar
Filed: 4 Aug 22
Utility
Kinase Inhibitors
13 Jul 23
Disclosed herein are 1H-indole-7-carboxamide derivatives as protein kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, pharmaceutical compositions comprising them, processes for preparing them and uses of such protein kinase inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function.
Craig Alan Coburn, Dange Vijay Kumar, Daniel John Buzard, Nidhi Arora
Filed: 2 Jun 21
Utility
Heterocyclic Kinase Inhibitors and Products and Uses Thereof
30 Mar 23
Luis Lopez, Craig Coburn, Martin W. Rowbottom, Iriny Botrous, Michelle Kasem
Filed: 26 Jun 20
Utility
Compositions and Methods of Treatment
9 Jun 22
Pharmaceutical compositions are provided containing tert-butyl-{[1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl]methyl}piperazine-1-carboxylate or a pharmaceutically acceptable salt thereof, more particularly to certain orally deliverable immediate release solid pharmaceutical compositions containing a pharmaceutically acceptable salt of tert-butyl-{[1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl]methyl}piperazine-1-carboxylate and orally deliverable delayed release solid pharmaceutical compositions containing tert-butyl-{[1-(4-chlorobenzyl)-3-hydroxy-2-oxo-1,2-dihydropyridin-4-yl]methyl}piperazine-1-carboxylate or a pharmaceutically acceptable salt of.
Barrett Levesque, Derek Moe, Nathaniel Santos Martinez
Filed: 19 Jul 21
Utility
Solid forms of(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl) benzoic acid
7 Sep 21
The present invention provides new salts and crystalline forms of leukadherin LA1 [(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid] according to Formula I.
Antonio J. Barbosa
Filed: 5 Nov 19
Utility
DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE and Related Compounds and Their Use In Treating Medical Conditions
13 May 21
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
Thomas Daniel Aicher, Donald J. Skalitzky, Peter L. Toogood, Chad A. Vanhuis
Filed: 11 Apr 19
Utility
Solid Forms OF(Z)-4-(5-((3-BENZYL-4-OXO-2-THIOXOTHIAZOLIDIN-5-YLIDENE)METHYL)FURAN-2-YL)BENZOIC Acid
7 Oct 20
The present invention provides new salts and crystalline forms of leukadherin LA1 [(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid] according to Formula I.
Antonio J. Barbosa
Filed: 4 Nov 19
Utility
Solid forms of (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
27 Jul 20
The present invention provides new salts and crystalline forms of leukadherin LA1 [(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid] according to Formula I.
Antonio J. Barbosa
Filed: 9 Jun 16
Utility
Heterocyclic Integrin Agonists
22 Apr 20
The present invention provides polycyclic oxothioxoimidazolidines, dioxoimidazolines, oxothioxooxazolidines, dioxooxazolidines, and related compounds, which are useful as integrin agonists.
Antonio J. Barbosa
Filed: 27 Dec 17
Utility
Quinoline derivative in crystal form
20 Apr 20
Crystals of [8-chloro-3-(4-chlorobenzyl)-4-difluoromethoxy-2-ethylquinolin-5-yloxy]acetic acid L-lysine salt, i.e., a crystal A which has peaks at diffraction angles 2θ=6.0°, 10.0°, 10.7°, 12.1°, 18.4°, 19.2° and 20.1° in powder X-ray diffraction spectra and a crystal B which has peaks at diffraction angles 2θ=6.0°, 11.7°, 12.4°, 15.2°, 16.4°, 20.3° and 22.6° in powder X-ray diffraction spectra.
Donald John Daley, John Gary Montana, George Hynd, Mitsuru Teramoto, Takahiro Ito
Filed: 24 Jul 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first